Literature DB >> 17289019

Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity.

Yu Fang1, Richard Sullivan, Charles H Graham.   

Abstract

Compared with tumour cells cultured as sparse monolayers, tumour cells cultured as confluent monolayers exhibit high levels of resistance to anti-cancer agents. This phenomenon is called confluence-dependent resistance (CDR). We determined the contribution of hypoxia-inducible factor-1 (HIF-1), a key transcriptional regulator of cellular adaptations to hypoxia, to the development of CDR in MDA-MB-231 breast cancer cells. Clonogenic assays revealed a density-dependent increase in resistance to doxorubicin. Cell density also correlated with increased staining for reductively activated pimonidazole (a marker for hypoxia), as well as with increased levels of the HIF-1alpha subunit and HIF transcriptional activity as determined by immunocytochemistry, Western blot, and luciferase reporter assays. Importantly, inhibition of HIF-1alpha expression with siRNA significantly attenuated CDR. Similarly, shaking of cultures attenuated CDR, pimonidazole immunostaining, HIF-1alpha accumulation, and HIF-1 transcriptional activity. Having established a link between HIF-1 and CDR, we used HIF-1alpha and HIF-1 transcriptional activity as markers to investigate the role of additional factors in the regulation of CDR. Confluence-dependent increases in HIF-1alpha accumulation and HIF-1 transcriptional activity were observed even in cells cultured at 0.1% O(2) as well as in sparse cultures incubated with conditioned medium from confluent monolayers. Serum deprivation in both sparse and confluent cultures also resulted in HIF-1alpha accumulation. These results reveal that, although pericellular hypoxia may be a major contributor to HIF-1 activity, changes in the levels of soluble factors may also play a role. This study demonstrates that HIF-1 is required for CDR.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17289019     DOI: 10.1016/j.yexcr.2006.12.004

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  25 in total

Review 1.  The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease.

Authors:  Imari Mimura; Masaomi Nangaku
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

2.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

3.  Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells.

Authors:  Xudong Tang; Qunzhou Zhang; Shihong Shi; Yun Yen; Xiangyong Li; Yuefei Zhang; Keyuan Zhou; Anh D Le
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

4.  Influence of a three-dimensional, microarray environment on human cell culture in drug screening systems.

Authors:  Luciana Meli; Eric T Jordan; Douglas S Clark; Robert J Linhardt; Jonathan S Dordick
Journal:  Biomaterials       Date:  2012-09-19       Impact factor: 12.479

5.  Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling.

Authors:  Swati Kushal; Brooke Bullock Lao; Laura K Henchey; Ramin Dubey; Hanah Mesallati; Nathaniel J Traaseth; Bogdan Z Olenyuk; Paramjit S Arora
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

6.  Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.

Authors:  Mario Niepel; Marc Hafner; Mirra Chung; Peter K Sorger
Journal:  Curr Protoc Chem Biol       Date:  2017-06-19

7.  Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.

Authors:  R D Spagnuolo; S Recalcati; L Tacchini; G Cairo
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

8.  Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate.

Authors:  T H Witney; M I Kettunen; D-e Hu; F A Gallagher; S E Bohndiek; R Napolitano; K M Brindle
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

9.  Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase.

Authors:  Mehdi A Fini; David Orchard-Webb; Beata Kosmider; Jeremy D Amon; Robert Kelland; Gayle Shibao; Richard M Wright
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

10.  Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.

Authors:  Sonia Aroui; Narendra Ram; Florence Appaix; Michel Ronjat; Abderraouf Kenani; Fabienne Pirollet; Michel De Waard
Journal:  Pharm Res       Date:  2008-12-13       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.